NASDAQ:SUNS | INVESTOR PRESENTATION N A S D A Q : S U N S | I N V E S T O R P R E S E N T A T I O N A TCG Company D I S C L A I M E R S Some of the statements contained in this presentation constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and we intend such statements to be covered by the safe harbor provisions contained therein. Such forward-looking statements are based on the current intent, belief, expectations and views of future events o ...

Financial Performance - Q1 2025 revenue reached $105 million, a 58% increase compared to Q1 2024[11] - Orders backlog as of March 31, 2025, stood at $6809 million, representing approximately 26 GWh[11] - Adjusted EBITDA loss was $432 million, a 17% increase compared to $369 million in Q1 2024[21] Commercial Growth - The commercial pipeline is valued at $156 billion, representing approximately 60 GWh[11] - Total commercial activity amounts to $291 billion, representing 115 GWh[24] - Booked orders totaled $92 million, including orders from 2 new customers[11] - The company secured 54 GWh in new Memorandums of Understanding (MOUs)[25] Operational Improvements - The company realized a 64% cost-out from product launch and a 77% volume-adjusted cost-out[16] - Manufacturing customer deliveries increased by 51% in Q1 compared to Q4 2024[15] - The company achieved significant output increases through subassembly automation, with terminal output up by 363% and bipolar output up by 332%[20] Guidance - The company reiterated its fiscal year 2025 revenue guidance of $150 million to $190 million, which is at least 10 times the full-year 2024 results[15]

FISCAL Q2 2025 Earnings Conference Call May 7, 2025 FORWARD-LOOKING AND CAUTIONARY STATEMENTS/NON-GAAP FINANCIAL INFORMATION Johnson Controls International plc cautionary statement regarding forward-looking statements Johnson Controls International plc has made statements in this communication that are forward-looking and therefore are subject to risks and uncertainties. All statements in this document other than statements of historical fact are, or could be, "forward-looking statements" within the meaning ...

Q1 2025 Financial Performance - Net sales reached $153.0 million, a 3.3% increase compared to the previous year, after adjusting for divestitures and strategic product rationalization[9] - Gross margin improved significantly to 41.9%, a 910 basis points increase year-over-year[9] - Adjusted EBITDA margin increased to 17.8%, a 460 basis points improvement compared to the previous year[9] - Free cash flow was negative at ($10.8) million, a decrease of ($28.6) million compared to the previous year[9] Growth Initiatives and Strategies - B2B channel experienced growth of approximately 2.5%[8] - DTC orders increased by over 10%, with third-party platforms like Amazon and eBay growing by more than 50%[8] - Product innovation and strategic pricing initiatives contributed $8.1 million in revenue[8] - The company is implementing proactive cost reductions and strategic sourcing initiatives to mitigate tariff impacts[8] Key Operational Improvements - In-stock percentage of the top 2,500 products increased by 2% year-over-year[9] - Operational efficiency improved by over $1 million year-over-year[9] - Past dues were reduced by 20% year-over-year[9] Financial Outlook - The company reaffirms its full-year 2025 net sales guidance of $580 million to $600 million, excluding the impact of tariffs, representing a year-over-year growth of 0.8% to 4.3%[39, 40] - Adjusted EBITDA for the full year 2025 is projected to be between $113 million and $130 million[39]

Annual Shareholders Meeting Unlocking Potential, Together May 7, 2025 Richard E. Thornburgh Chairman Martina Cheung President and CEO Tasha Matharu Deputy General Counsel & Corporate Secretary Tasha Matharu Deputy General Counsel & Corporate Secretary 2 2 2025 Annual Shareholders Meeting Rules of Conduct To submit questions during the Annual Meeting, please log in to the meeting as a shareholder using your 15-digit control number and follow the instructions. https://meetnow.global/MTWC7R7 3 –Shareholders ar ...

Financial Performance - Revenues for Q2 FY25 reached $35 billion, a 1% increase compared to $3465 billion in Q2 FY24[10, 23] - Adjusted EBITDA for Q2 FY25 was $268 million, a 3% increase from $260 million in Q2 FY24, with a margin of 77%[10, 23] - Adjusted Diluted EPS for Q2 FY25 was $053, compared to $051 in Q2 FY24[10, 23] - Free Cash Flow for Q2 FY25 was $53 million[10, 30] Backlog and Business Development - The company's backlog stands at $45 billion, with a YTD book-to-bill ratio of 10x[10, 14] - Approximately $29 billion in pending awards are anticipated, with a FY25 submits target of over $35 billion[18] Divestiture and Strategy - The company announced a definitive agreement to divest its Rapid Solutions product business for $360 million, expecting $325 million in after-tax proceeds[21] - The divestiture of Rapid Solutions accounts for approximately 1% of annual Revenues and Adjusted EBITDA[21] Fiscal Year 2025 Outlook - The company reaffirms its prior guidance mid-points for Fiscal Year 2025, with revenue contributions primarily from existing or recompete business (98%) and new business (2%)[37] - The company projects Free Cash Flow between $475 million and $525 million, Adjusted Diluted EPS between $200 and $220, Adjusted EBITDA between $1065 billion and $1095 billion, and Revenues between $1385 billion and $1415 billion[37]

First Quarter 2025 Financial Results & Business Update Conference Call May 7, 2025 Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches,research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in ...

AVADEL Pharmaceuticals plc (NASDAQ: AVDL) First Quarter 2025 Earnings Slides TRANSFORMING MEDICINES TO TRANSFORM LIVES A BIOPHARMACEUTICAL COMPANY FOCUSED ON 2 Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, ...

Financial Performance - Total revenue for 1Q25 was $752 million[15] - Cloud communications revenue for 1Q25 reached $545 million[15] - Adjusted EBITDA for 1Q25 grew by 50% year-over-year to $88 million[15] - Free cash flow for 1Q25 increased by 94% year-over-year to $50 million[15] - The company is raising full year 2025 total revenue growth guidance to 9-11% when normalized for 2024 cyclical political campaign revenue[36, 37] Revenue Growth - Total revenue grew by 7% year-over-year in 1Q25[18] - Cloud communications revenue grew by 6% year-over-year in 1Q25[18] - Enterprise Voice revenue grew by 26% year-over-year[19] Customer Metrics - Net Retention Rate (NRR) was 116%[12, 23] - Average annual customer revenue increased by 20% year-over-year[23] Gross Margin - Non-GAAP gross margin increased to 59%[44]

Business Highlights - Rhythm Pharmaceuticals is on track to complete U S and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity (HO) in Q3 2025[9] - The company experienced solid patient demand growth for IMCIVREE (setmelanotide) in Q1 2025[9] - Data readout for the Phase 2 trial of oral bivamelagon in acquired HO is expected in Q3 2025[9] - Rhythm Pharmaceuticals expects its current cash runway to extend into 2027[9] Clinical Trial Results (Setmelanotide in Acquired HO) - The Phase 3 trial showed a statistically significant BMI reduction of 16 5% in the setmelanotide arm compared to baseline[13] - The placebo-adjusted difference in BMI reduction from baseline was 19 8% (P<0 0001)[14] - Significant BMI reductions were observed in both adults (16 3%) and children (16 8%) treated with setmelanotide[18] - A vast majority of patients with acquired HO completed the Phase 3 trial and transitioned to an extension study[27] Financial Performance (Q1 2025) - Net product revenue was $37 7 million, compared to $26 0 million for the three months ended March 31, 2024[63] - Cash, cash equivalents, and short-term investments totaled $314 5 million as of March 31, 2025[63] - The company anticipates non-GAAP operating expenses between $285 million and $315 million for 2025[66]